Healthtech firm announces IPO

Personal healthcare company Integumen has announced its intention to float on the London Stock Exchange.

Integumen, which specialises in skin technology, intends to raise £2.25m in the placing. Its expected market capitalisation on admission will be £8.25m.

In the UK, the company is registered in North Yorkshire, with a York-based Labskin laboratory, R&D facilities and offices. its head office is based in Dublin in the Republic of Ireland.

Integumen specialises in anti-ageing creams, blemish control products, wound and oral care for hygiene. It was incorporated in May 2016 and consists of four wholly-owned subsidiaries: UK-based Innovenn and Lifesciencehub, TSpro in Germany, and Integumen Inc in the United States.

SPARK Advisory Partners Limited is acting as Nominated Adviser, and Turner Pope Investments (TPI) Ltd as Broker, to the Company.

Declan Service, CEO of Integumen said: “We have acquired four highly scalable businesses to bring together an impressive portfolio of technologies and products we can develop and commercialise in our chosen markets and an experienced management team which has a track record of innovation, deal execution, and creating value.”

“The late stage development of many of our products means Integumen is now focused on their marketing, sale and distribution. We have developed strong partnership relations which provide us with an international sales and distribution network to grow the business, and believe that by investing in further development or commercialisation, Integumen will be well-positioned to capitalise on these growing markets.”